Signet Announces Availability of Two Monoclonal Antibodies
Complete the form below to unlock access to ALL audio articles.
Signet Laboratories, Inc. has announced the availability of two monoclonal antibodies, EGFR, clone F4 and VEGF, clone VG-1.
EGFR, clone F4, has been implicated in the development and progression of a number of human solid tumors including lung, breast, prostate, colon, ovary, head, and neck.
VEGF, clone VG-1, is a secreted glycoprotein that is a potent and specific mitogen for vascular endothelial cells that stimulates angiogenesis during embryonic development and tumor formation.
Signet's EGFR and VEGF antibodies are designed to offer researchers a valuable tool for cancer research.
These antibodies complement Signet's current product portfolio which includes markers such as D2-40, Cyclin D1, Cyclin E, HE4, and Hepsin.